Skip to contentpdufa.bio

ALN-6400

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

ALN-6400 is an Alnylam Pharmaceuticals, Inc. program in healthy volunteers. Its next catalyst is a Readout in Dec 2026.

ALNY catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: Healthy volunteers; Hereditary hemorrhagic telangiectasia (HHT). Sponsor: Alnylam Pharmaceuticals, Inc. (ALNY). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026ALNYReadout · Feb 2027ALNY

Questions

When is ALN-6400's next FDA decision or readout?

The next tracked catalyst for ALN-6400 is a Readout in Dec 2026.

What happened at ALN-6400's most recent FDA decision?

No FDA decision for ALN-6400 is in our archive yet.

What is ALN-6400 used for?

In our records ALN-6400 is under review or in development for Healthy volunteers; Hereditary hemorrhagic telangiectasia (HHT).

Who makes ALN-6400?

Alnylam Pharmaceuticals, Inc. (ALNY).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.